this is a pharma play with several solid products but had poor management over the years and never got the product solidly on line. Now cebt has cost the guy his job and the investors equity dearly. I took note when John Sedor took over almost a year ago and started to cut costs and better market the product. Since then he has done a reverse split so the co. could poss. dilute yet to cover debt. After that the co. would be on solid footing. Insts have taken note and started to readd this to portfolio. It is also ripe for a big pharma to take over where they look at long term income revenue streams where the current debt doesn't mean a whole lot to absorb...so a ripe buyout play......anyhow the stock has been holding well now after bottom just around 3....bo cld be anywhere in 30 plus......lt if co. went on its own, the product is such revs could be huge....anyhow...in and staying in to see the out come....
